Dynavax Technologies Corporation (DVAX) Raised to “Hold” at ValuEngine

ValuEngine upgraded shares of Dynavax Technologies Corporation (NASDAQ:DVAX) from a sell rating to a hold rating in a research note released on Thursday morning.

A number of other analysts have also recently weighed in on DVAX. Cowen and Company restated an outperform rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a report on Thursday, August 10th. Royal Bank Of Canada upgraded shares of Dynavax Technologies Corporation from a sector perform rating to an outperform rating and raised their target price for the stock from $7.00 to $26.00 in a report on Monday, July 31st. William Blair restated an outperform rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a report on Wednesday, August 9th. J P Morgan Chase & Co upgraded shares of Dynavax Technologies Corporation from a neutral rating to an overweight rating and raised their target price for the stock from $6.00 to $27.00 in a report on Monday, July 31st. Finally, BidaskClub cut shares of Dynavax Technologies Corporation from a buy rating to a hold rating in a report on Monday, July 31st. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Dynavax Technologies Corporation currently has a consensus rating of Buy and a consensus price target of $24.80.

Shares of Dynavax Technologies Corporation (DVAX) opened at 19.60 on Thursday. Dynavax Technologies Corporation has a 52 week low of $3.20 and a 52 week high of $20.15. The stock’s market cap is $1.07 billion. The stock’s 50 day moving average price is $15.83 and its 200 day moving average price is $8.93.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.09. The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.15 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. During the same period last year, the firm posted ($0.75) earnings per share. Equities research analysts anticipate that Dynavax Technologies Corporation will post ($1.58) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Dynavax Technologies Corporation (DVAX) Raised to “Hold” at ValuEngine” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/09/10/dynavax-technologies-corporation-dvax-raised-to-hold-at-valuengine.html.

A number of institutional investors have recently bought and sold shares of DVAX. Cubist Systematic Strategies LLC boosted its stake in Dynavax Technologies Corporation by 54.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 3,700 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its stake in Dynavax Technologies Corporation by 16.5% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 1,700 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in Dynavax Technologies Corporation in the 1st quarter worth approximately $121,000. Bank of America Corp DE boosted its stake in Dynavax Technologies Corporation by 2.3% in the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 456 shares during the period. Finally, Legal & General Group Plc boosted its stake in Dynavax Technologies Corporation by 18.5% in the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 1,950 shares during the period. 60.23% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply